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Abstract Ischemia/reperfusion injury (IRI) is crucial in the
pathology of major cardiovascular diseases, such as
stroke and myocardial infarction. Paradoxically, both
the lack of oxygen during ischemia and the replenish-
ment of oxygen during reperfusion can cause tissue
injury. Clinical outcome is also determined by a third,
post-reperfusion phase characterized by tissue remodel-
ing and adaptation. Increased levels of reactive oxygen
species (ROS) have been suggested to be key players in
all three phases. As a second paradox, ROS seem to
play a double-edged role in IRI, with both detrimental
and beneficial effects. These Janus-faced effects of ROS
may be linked to the different sources of ROS or to the
different types of ROS that exist and may also depend
on the phase of IRI. With respect to therapeutic impli-
cations, an untargeted application of antioxidants may
not differentiate between detrimental and beneficial
ROS, which might explain why this approach is clini-
cally ineffective in lowering cardiovascular mortality.
Under some conditions, antioxidants even appear to be
harmful. In this review, we discuss recent breakthroughs
regarding a more targeted and promising approach to
therapeutically modulate ROS in IRI. We will focus on
NADPH oxidases and their catalytic subunits, NOX, as
they represent the only known enzyme family with the
sole function to produce ROS. Similar to ROS, NADPH
oxidases may play a dual role as different NOX iso-
forms may mediate detrimental or protective processes.
Unraveling the precise sequence of events, i.e., deter-
mining which role the individual NOX isoforms play in
the various phases of IRI, may provide the crucial
molecular and mechanistic understanding to finally ef-
fectively target oxidative stress.
Keywords NADPH oxidases . NOX . Ischemia/reperfusion
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Introduction
Stroke and myocardial infarction (MI) are two major
causes of death and disability in Western countries.
Both are caused by organ ischemia followed by varying
degrees of reperfusion. Reactive oxygen species (ROS)
are thought to be the key players in this ischemia/
reperfusion injury (IRI) [1, 2]. Consequently, treatment
of IRI should be directed to these key players. The
untargeted use of antioxidants, however, failed to show
any clinical benefits after stroke [3, 4] or MI [5, 6].
Indeed, specifically targeting the pathological source of
ROS may provide a better therapeutic approach. Among
such potential ROS sources, NADPH oxidases are the
only known enzymes with the sole function of produc-
ing ROS. In the cardiovascular system, NAPDH oxi-
dases account for a major part of the ROS formed, not
only during IRI but also under physiologic conditions
[7]. Here, we review the pathophysiology of IRI, focus-
ing on NADPH oxidases as new potential targets for
therapeutic interventions.
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Ischemia/reperfusion injury: two paradoxes
During ischemia or the subsequent reperfusion, damage can
occur in cells or tissues, which often is irreversible. This
damage is referred to as IRI [1, 8]. IRI can be divided into
three phases.
During the first, ischemic phase, interruption of the blood
flow to an organ causes a (temporary) lack of oxygen and
nutrients [1, 2, 8, 9]. The generation of adenosine triphos-
phate (ATP) via oxidative phosphorylation is disturbed dur-
ing ischemia, causing cells to alter their metabolism. The
reduced availability of ATP limits the activity of the ATP-
dependent Na+/K + pump [1, 2], which constraints the
outflow of calcium via the Na+/Ca2+ exchanger [8]. This
results in calcium overload, causing structural disorganiza-
tion as well as apoptotic and necrotic death of cells [2, 8, 9].
In addition, chemokines and adhesion molecules promote a
proinflammatory state [1, 2, 10]. Moreover, the altered
cellular metabolism leads to an accumulation of precursors
of oxidative phosphorylation, and it causes damage to or
conformational changes of enzymes such as xanthine oxi-
dase. These latter processes are not directly detrimental to
cells, but they become important in the next phase of IRI by
increasing ROS generation [1, 8, 9].
The second phase of IRI constitutes the reestablishment
of blood flow and thus the reintroduction of oxygen. Al-
though oxygen is needed for survival, it can also be detri-
mental because it can be converted to ROS such as
hydrogen peroxide (H2O2) and superoxide (O2
−) [1]. ROS
can directly damage cells via a number of mechanisms, e.g.,
by influencing the opening probability of the mitochondrial
permeability transition pore [11], by causing lipid peroxida-
tion [1], by activating matrix metalloproteinases [12], or by
oxidizing DNA [12]. However, ROS may also damage cells
in a more indirect manner: They can, e.g., interact with nitric
oxide (NO), fatty acids, or free iron (Fenton reaction). This
often results in the formation of even more cytotoxic sub-
stances, such as peroxynitrite, peroxyl radicals, and hydrox-
yl radicals [11]. In addition, ROS can enhance the
inflammatory response by the upregulation of chemokines
and adhesion molecules [1, 10]. Thus, the reperfusion phase
can be seen as a “double-edged sword” [13]: On one hand,
there is a cellular demand for the replenishment of oxygen,
while on the other hand, this oxygen results in ROS forma-
tion. The paradoxical role of oxygen in the first two phases
is called the “oxygen paradox” [9].
The second ROS paradox shows up in a later and more
chronic phase of IRI, the post-reperfusion phase. In contrast
to their detrimental role in the acute phases, here, ROS affect
several tightly regulated processes that lead to an optimal
environment for survival: Angiogenesis is induced by ROS
through the upregulation or activation of vascular endothe-
lial growth factor (VEGF) and hypoxia-inducible factor
(HIF) [14, 15]. The proliferation and differentiation of vascu-
lar smooth muscle cells (VSMC), needed for vascular remod-
eling, are also affected by ROS [14, 15]. These beneficial roles
of ROS are also seen during permanent ischemia.
NADPH oxidases as a source of ROS in IRI
Most sources of ROS (see the “Other sources of ROS in
IRI” section) only generate ROS “by accident,” i.e., as a by-
product of the metabolism they are involved in or during
nonphysiologic conditions, such as ischemia [16–21].
NADPH oxidases stand out from these sources of ROS, as
they constitute the only enzyme family with the sole func-
tion to produce ROS, not only in disease, but also in phys-
iology [22]. NADPH oxidases are abundantly expressed in
the vasculature, where they are emerging as the key pro-
ducers of ROS [7, 23–26]. Depending on the phase of IRI,
NADPH oxidases can be either detrimental or protective.
Thus, NADPH oxidases also have a double-edged role,
similar to their substrate, oxygen.
Interestingly, several drugs used to treat cardiovascular
diseases regulate the expression and activity of NADPH
oxidases. For example, statins prevent the translocation of
the NADPH oxidase subunit Rac1 to the cell membrane
[27]. This translocation is one of the essential steps in the
activation of some NOX isoforms [28]. Thus, some of the
pleiotropic effects of statins can be attributed to their ability
to decrease NADPH oxidase-mediated ROS production [27,
29, 30]. Angiotensin-converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARB) reduce angiotensin
II formation and angiotensin II-mediated AT1 receptor acti-
vation, respectively. Since angiotensin II signaling is a po-
tent stimulus for NADPH oxidase expression and activity
[29, 30], ACE inhibitors and ARB decrease NADPH oxi-
dase expression and activation.
Biochemistry of NADPH oxidases
NADPH oxidases are multiprotein complexes. Seven iso-
forms of their catalytic subunits exist, annotated as NOX1–5
and DUOX1–2 (recently also termed as NOX6–7). They
contain six or seven transmembrane spanning domains,
respectively. They catalyze the electron transport from
NADPH to molecular oxygen, thereby producing ROS [7,
22, 31, 32]. All isoforms have two heme groups, an FAD
and a NADPH binding site [26]. NOX2 was the first de-
scribed isoform. It was discovered in neutrophils, where it
mediates oxidative burst and is thus important for innate
host defense [22–24, 28]. In the vasculature, NOX2 is active
in almost all vascular wall cells [33, 34]. In the cardiovas-
cular system, next to NOX2, NOX1, NOX4, and NOX5 are
also expressed. The latter, however, is not present in rats and
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mice [24, 28, 32]. NOX1 is expressed in endothelial cells
(EC), VSMC, and adventitial fibroblasts [35]. NOX4, the
most abundantly expressed isoform, is found in EC and
VSMC [24, 35]. Its expression and activity seem to be
especially prominent in the cerebral vasculature [36], with
gender-specific differences [37]. NOX5 is located in vascu-
lar EC [38] and VSMC [39]. The NOX isoforms not only
vary in their expression pattern but also in their subcellular
localizations. For example, NOX4, is found in the nucleus
and might be present in mitochondria [40], making NOX4 a
potential source of mitochondrial ROS. NOX1 colocalizes
with caveolin-1 [41], associating it with caveolae and eNOS
uncoupling (see below) [42]. Furthermore, the various NOX
isoforms require different cytosolic subunits for activity,
such as activator and organizer proteins or Rac1 [43, 44].
NOX4 stands out from the other NOX isoforms as it is
constitutively active and produces H2O2 as its main product
[28]. An important feature of NOX5 is that it does not need
any of the cytosolic subunits. Importantly, it is directly
activated by calcium through calcium binding to its EF hand
motifs [24]. NOX6–7 (formerly called DUOX1–2) play
probably no (major) role in the vasculature. Figure 1 and
Table 1 give an overview of the characteristics of the iso-
forms expressed in the cardiovascular system.
Validation of NADPH oxidases as therapeutic targets for IRI
NADPH oxidases during acute ischemia
NADPH oxidases have been proposed to be oxygen sensors
and thus to be involved in the ischemic phase of IRI (Fig. 2)
[45–48]. They are also likely to interact with the HIF path-
way (see below) [49–55].
Oxygen sensing is the endogenous ability of tissues to
respond to changes in oxygen tension. It occurs in specialized
cells such as the glomus cells of the carotid body and the
neuroepithelial bodies in the lung. While NADPH oxidases
are expressed in these tissues [47, 48], a true functional role in
oxygen sensing is disputed [47, 48, 56–58]. In this review, we
focus on true IRI; discussing the mechanisms of oxygen
sensing in more detail is beyond the scope of this review.
First evidence for a role of NADPH oxidases in ischemia
comes from studies showing an altered expression on
mRNA or protein levels of NADPH oxidases caused by a
Fig. 1 The four vascular NOX isoforms need different subunits for
their activation, have different subcellular localizations, and produce
different types of ROS. NOX2 is the first described isoform of the
NADPH oxidase family. It consists of a six-transmembrane-spanning
catalytic domain. The membrane-bound subunit p22phox and cytosolic
subunits p47phox, p67phox, and p40phox need to assemble for NOX2
activation. In addition, the small G protein Rac binds to this complex.
NOX2 is mainly localized in intracellular vesicles, but also in plasma
membranes (PM). The basic structure of NOX1 is similar to NOX2.
However, NOX1 interacts with the p47phox and p67phox analogs,
NOXO1 and NOXA1, although at least in recombinant systems, it is
also active upon interaction with p47phox and p67phox (not shown).
NOX1 activity also depends on p22phox and Rac. Similar to NOX2,
NOX1 is located in the PM. In addition, it was suggested to be located
in caveolae. NOX3 appears not to be expressed in the vasculature but
in the inner ear [28, 31]. NOX4 is different from the other vascular
isoforms in that it only interacts with p22phox but does not rely on
other cytosolic subunits for its activation. It was suggested that NOX4
is not only located in the plasma membrane, but also in membranes of
the endoplasmic reticulum (ER) and in mitochondria. NOX4 is consti-
tutively active, but can be further activated by several factors such as
angiotensin or growth factors. PolDip2 has been described as a binding
protein that can activate NOX4 [152]. NOX4 has been suggested to
also or even predominantly generate hydrogen peroxide (H2O2).
NOX5 has mainly been found in the ER in addition to its localization
in the PM. It produces superoxide and is active without any subunits.
An increase in calcium activates NOX5 mediated by its calcium
binding domains, i.e., the EF hands. In addition, the C terminus of
NOX5 has a calmodulin-binding domain
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change in oxygen tension. In pulmonary artery smoothmuscle
cells (PASMC), EC, pulmonary epithelial cells, and PC12
cells, a cell line from pheochromocytoma of rat adrenal me-
dulla [51, 53, 54], either NOX1, NOX2, or NOX4mRNA and
protein levels are upregulated during hypoxia. In vivo, an
upregulation of NOX4 was also shown in mouse lungs after
hypoxia [51, 59]. Similarly, mRNA levels of the NADPH
oxidase subunits p22phox, p47phox, and p67phox increased in
response to hypoxia in human umbilical vein endothelial cells
(HUVEC) [60]. In the brain of rats and mice, upregulation of
NOX2, NOX4, and p47phox mRNA levels was reported after
stroke induced by ischemia/reperfusion (I/R) [61–63]. An
increase in NOX2, NOX4, p22phox, and p67phox mRNAwas
also found after MI in mice [64–66]. Furthermore, NOX4
mRNA and protein levels were upregulated in peripheral
muscles after hindlimb ischemia in mice [67]. Taken together,
the aforementioned studies indicate that NOX isoforms are
upregulated at the mRNA level. However, a concomitant
increase at the protein or functional level has not always been
reported. Therefore, further studies are necessary.
The effects of hypoxia on NADPH oxidases and reciprocal
effects of NADPH oxidases on hypoxic signaling pathways
seem to be mediated by different regulatory pathways, some of
them involving hypoxia-inducible transcription factors of the
HIF family [68]. HIFs are composed of an oxygen-sensitiveα-
subunit and a constitutively expressed β-subunit also termed
aryl hydrocarbon receptor nuclear translocator [69].
Interactions between NADPH oxidases and HIF proteins
have been shown for different NOX isoforms and NADPH
oxidase subunits [68, 70]. ROS derived from NADPH oxi-
dases can upregulate HIF-1α mRNA and protein levels [71].
In VSMC, HIF-1α is induced by thrombotic factors. This
induction and its further activation depend on Rac1 and
p22phox [52, 72]. Further data indicate that NOX2 and
NOX4 play a role in regulating HIF-1α levels in EC, thereby
modulating angiogenic activity [73]. In PASMC, NOX4 in-
duced HIF-1α and HIF-2α levels by interfering with the
activity of the HIF-α-modifying prolyl hydroxylases [50].
These data indicate that NADPH oxidases can modulate HIF
activity by several mechanisms, including transcriptional
upregulation of HIF-1α through the activation of NFκB
[71]. In addition, NADPH oxidases have been reported to
mediate posttranslational stabilization of HIF-1α proteins by
interfering with the HIF-degrading machinery [50].
Both transient and stable overexpression of NOX1 in
A549 cells resulted in increased HIF-1-dependent target
gene expression [53]. Also, increased HIF-1α protein was
found both during hypoxia and normoxia in these NOX1-
transfected cells [53].
On the other hand, expression of active Rac1 decreased
nuclear HIF-1α levels in HepG2 cells and primary rat hep-
atocytes under hypoxia [74], while opposite effects were
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subunits might thus have specific roles, and/or the redox
sensitivity of different cells and tissues might be specific.
NADPH oxidases not only regulate HIF-1α and HIF-2α,
but HIF can vice versa also affect NADPH oxidases. In mice
with a heterozygous defect in HIF-1α and thus reduced
HIF-1α levels, NOX2 mRNA and protein did not increase
in the cortex and brainstem after exposure to intermittent
hypoxia, while in wild-type (WT) mice, NOX2 was upregu-
lated [54]. Fibroblasts from HIF-1α heterozygous mice had
a lower basal HIF-dependent reporter gene activity, and
NOX2 mRNA levels did not increase after hypoxia, but
they did increase in fibroblasts from WT mice [54]. Simi-
larly, in endothelial-specific HIF-1α knockout (KO) mice,
NOX2 mRNA expression and protein levels were reduced
even when adding the NOX2-stimulator urotensin-II [73].
Overexpression of HIF-1α in PC12 cells also increased
NOX2 mRNA and protein levels as well as NADPH oxidase
activity after intermittent hypoxia [55]. Importantly, a func-
tional HIF binding site in the proximal promoter of the
NOX2 gene was recently identified [73], and thus, NOX2
was added to the list of genuine HIF-1 target genes. As such,
HIF-1 can regulate the expression of NOX2 and thereby
ROS production by NOX2. For NOX4, a decrease of its
mRNA levels in PASMC during hypoxia after treatment of
the cells with shRNA against HIF-1α was reported [51].
Vice versa, overexpression of HIF-1α resulted in elevated
NOX4 mRNA and protein levels. ROS production also
increased after overexpression of HIF-1α, but only when
NOX4 was present [51]. Similarly to NOX2, a functional
HIF binding site was identified in the NOX4 promoter, thus
adding also NOX4 to the list of direct HIF target genes [51].
These findings suggest that ROS-dependent activation of
HIF can induce the expression of several NADPH oxidase
subunits under normoxic conditions, thus promoting ROS-
mediated signaling pathways. Under low oxygen condi-
tions, such as ischemia, the rapid stabilization and activation
of HIF may be the primary event responsible for the upre-
gulation of NADPH oxidases. This process may help cells
and tissues to adapt at least partially to the decreased sub-
strate availability under these conditions, thereby also
allowing a certain restoration of ROS levels under hypoxia.
However, whether NADPH oxidases can also be activated
under hypoxia without concomitant increase in subunit
availability is not clear and precise mechanisms and inter-
actions of NADPH oxidase-derived ROS under these con-
ditions still need to be elucidated.
Fig. 2 The role of NADPH oxidases in the three phases of IRI. During
the ischemic phase, the lack of oxygen results in decreased ATP produc-
tion, increasing the calcium concentration, which ultimately results in
necrosis. In addition, the drop in oxygen upregulates NADPH oxidases
via stimulation of HIF-1α. NADPH oxidases can also activate HIF-1α,
initiating a positive feedback loop. When a reintroduction of oxygen
occurs during the reperfusion phase, NADPH oxidases produce large
amounts of ROS. These ROS then enhance the inflammatory response
by upregulation of adhesion molecules and chemokines, which activate
and attract leucocytes. Inflammation and edema ensue. ROS can also
have direct cytotoxic effects. Together with the inflammation, this ulti-
mately results in necrosis and apoptosis of cells. ROS production also
occurs during the post-reperfusion phase. In this phase, a certain level of
ROS is needed to ensure a proper stimulation of angiogenesis via VEGF
activating EC and remodeling via the NFκB pathway activating VSMC.
This leads to a better environment for tissue survival
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NADPH oxidases during reperfusion
Upon reintroduction of oxygen, NADPH oxidases are be-
lieved to generate large amounts of ROS, which have direct
cytotoxic effects [11, 12] (Fig. 2). For example, after I/R of the
lung or the brain, lipid peroxidation, protein nitration, and
oxidative DNA damage were smaller in NOX2 KO [76] or
p47phox KO mice compared to WT mice [77, 78]. Similar
results were found when apocynin, an unspecific NADPH
oxidase inhibitor [30, 79], was applied to WT mice [76, 78].
Apocynin and diphenylene iodonium (DPI), another unspe-
cific NADPH oxidase inhibitor, also reduced the increases in
lipid peroxidation, cell death, and apoptosis after I/R in H9c2
cells [80, 81]. However, these results should be interpreted
with caution because of the lack of specificity of these inhib-
itors: apocynin has antioxidant properties [79] and DPI is a
general flavoprotein inhibitor [82]. The more specific
NADPH oxidase inhibitor VAS2870 given to WT mice 2
and 12 h after cerebral I/R, which was induced by transient
middle cerebral artery occlusion, decreased infarct size, ROS
levels, tissue nitration, apoptosis, and brain edema. VAS2870
also improved the functional outcome in WT mice after the
induction of ischemic strokes [62]. NOX4 KO mice showed
the same decreases in damage as VAS2870-treated WT mice,
while treatment of NOX4 KO mice with VAS2870 did not
have an additional protective effect [62]. This strongly
suggests that NOX4 contributes to cerebral IRI. Togeth-
er, these studies show that NADPH oxidases-derived
ROS, particularly NOX4, are likely to be involved in the
direct cytotoxic effects of IRI in the brain.
Evidence for the role of other NOX isoforms in cerebral
IRI is contradictory. No effect of NOX1 or NOX2 in brain
IRI was found in the study mentioned above [62]. Two other
studies showed no role [83] or a detrimental role [84],
respectively, of NOX1 in stroke. Data concerning the role
of NOX2 are also conflicting [62, 76, 77, 84–87]. For a
more detailed discussion of the role of NADPH oxidases in
brain I/R, we refer to [88].
NADPH oxidases can also indirectly cause damage by
enhancing the inflammatory response [22]. Neutrophils,
which express NOX2, are the primary source of ROS after
heart I/R in dogs [89]. Further, neutrophil infiltration was
reduced after brain I/R in NOX2 KO mice compared to WT
mice. Similarly, neutrophil infiltration was attenuated in the
lungs of p47phox KO mice or of mice treated with apocynin
[76, 78]. However, again, apocynin is not specific for
NADPH oxidases. Furthermore, after lung I/R, proinflam-
matory cytokine levels including TNF-α, IL-6, IL-1β, and
MCP-1 in lungs were lower in p47phox KO mice compared
to WT mice [78]. This was also observed in the brain after I/
R [76]. Here, the ischemic stroke induced the disruption of
the blood–brain barrier (BBB), which contributes to inflam-
mation via increased permeability and subsequent tissue
swelling after brain I/R. This BBB disruption was reduced
in NOX2 KO mice compared to WT mice [86].
In an isolated perfused lung I/R model, edema and vas-
cular permeability were reduced in lungs from NOX2 KO
mice, but neither in lungs from NOX1 KO mice nor in
NOX4 KO mice [90]. Together, these data suggest a role
of NOX2 or p47phox in the inflammatory reaction and che-
motaxis during IRI. The regulation of different cytokines in
different organs suggests a cell-specific or organ-specific
effect of NOX2. With respect to the other NOX isoforms,
no solid data on their involvement in inflammation and
chemotaxis after IRI are available.
NADPH oxidases during post-reperfusion and chronic
ischemia
ROS are not only toxic during acute IRI, they are also key
signaling molecules in pathways mediating cell proliferation
and differentiation [7, 22, 91–93], which are needed for both
angiogenesis and remodeling (Fig. 2). During the post-
reperfusion period or during chronic ischemia, NADPH oxi-
dases might thus have a protective role, showing the second
edge of the NADPH oxidase sword [94–97]. On one hand,
ROS can mediate autophosphorylation of vascular endothelial
growth factor receptor 2 (VEGFR2), which leads to the acti-
vation of downstream signaling pathways [96]. In addition, by
interacting with HIF-1α, ROS can activate VEGF and other
targets, which protect and activate vascular proliferative
responses such as plasminogen activator inhibitor-1 (PAI-1)
[68, 70, 71].
On the other hand, VEGF can activate NADPH oxidases
via Rac1, leading to increased ROS production [98]. This
feedback loop ultimately results in increased VEGF-induced
angiogenesis. In nonvascular cells, there is also a negative
feedback loop involved, in which Rac1 inhibits HIF-1 and
PAI-1 and thus decreases angiogenesis [74].
The nonspecific NADPH oxidase inhibitor, DPI, and the
antioxidant, N-acetylcysteine, decreased VEGF-induced
ROS levels in HUVEC, as did NOX2 antisense constructs
[98]. p47phox downregulation in HUVEC also led to de-
creased VEGF-mediated phosphorylation of downstream
mediators [99]. VEGF-induced neovascularization in a
sponge implant model was also reduced in NOX2 KO mice
compared to WT mice [98]. Together, these data clearly
point to a role of NADPH oxidases in the VEGF signaling
pathway in vascular cells at several levels. However, the
importance of NOX2 for angiogenic responses is not limited
to VEGF signaling. Recently, it was reported that the vaso-
active peptide urotensin-II can also induce angiogenesis,
and this response was inhibited in vitro by downregulating
NOX2 in EC using shRNA. Similarly, vascular sprouting
into a Matrigel plug was disrupted in NOX2 KO mice, but
not in WT mice [73].
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After hindlimb ischemia, flow recovery and capillary
density were reduced in NOX2 KO mice [100, 101]. How-
ever, there is also evidence for a normal collateral growth in
NOX2 KO mice, with only a dysfunction of the newly
formed vessels, resulting in compromised perfusion [102].
In addition, when adding oxidative stress triggers, such as
smoking or diabetes, the impairment of new vascularization
was less pronounced in NOX2 KO mice compared to WT
mice [103, 104]. Thus, while NOX2 clearly seems to be
involved in promoting angiogenesis in vivo, it is the specific
environment (i.e., oxidative stress or not) that finally deter-
mines the overall impact of NOX2 on these responses.
During remodeling in the chronic phase of IRI, NOX2
seems to play a detrimental role. NOX2 or p47phox KO mice
subjected to MI displayed less dilatation of the left ventricle,
less hypertrophy, and less interstitial fibrosis along with an
increased survival after 4 weeks [64, 65]. Interestingly,
infarct sizes did not differ between KO and WT mice both
after 24 h and 4 weeks [64, 65]. Others did not find any
difference between NOX2 KO and WT mice in infarct size,
apoptosis, collagen content, or inflammation after MI [66,
105]. However, some studies neither used littermates as
control mice nor sham-operated animals. This is relevant
when interpreting these results. Furthermore, differences in
mouse strains can influence heart remodeling [106]. Also,
p47phox KO and p47phox heterozygous mice had similar
infarct sizes and left ventricular functions 24 h after I/R of
the heart [107]. However, 24 h of reperfusion in the heart
can be rather regarded as an acute reperfusion phase; thus,
these results suggest that there is no role for NOX2 and
p47phox in acute heart IRI. Rather, there may be an effect in
the post-reperfusion phase. Although the data are contradic-
tory, most studies suggest a rather detrimental role of NOX2
in long-term remodeling after MI.
NOX1 has been shown to be involved in angiogenesis in
tumors [108], but data in I/R models are missing. NOX1-
overexpressing transgenic mice showed an increased hyper-
trophy of VSMC in response to angiotensin II [109]. More-
over, NOX1 may be involved in cell growth and
transformation, not only in the vasculature but also in
tumor-forming cells [110, 111].
For NOX4, data suggest a protective role in the chronic
phase of IRI. siRNA against NOX4 reduced tube formation
and wound healing responses in HMEC and HUVEC and
also inhibited both basal and VEGF-induced cell migration
or proliferation [67, 112]. NOX4 overexpression increased
these responses [67, 112]. In line, similar responses of cell
migration and proliferation were found after overexpressing
or silencing NOX4 in human and bovine EC grown on
Matrigel [67]. However, studies using siRNA against
NOX4 should be interpreted with caution, since not all
siRNAs specifically downregulate NOX4 and some may
also affect other NOX isoforms [113].
In mice injected with adenoviral NOX4 into the hin-
dlimb, blood flow was increased after ligation of the femoral
artery compared to nontreated animals [67]. Accordingly,
blood flow restoration in NOX4 KO mice was reduced after
hindlimb ischemia [114]. Furthermore, aortas of
endothelial-specific NOX4 transgenic mice displayed in-
creased sprouting ex vivo [67]. Thus, a protective role for
NOX4 in angiogenesis during chronic ischemia is likely.
In addition, an involvement of NOX4 in the regulation of
VSMC growth and differentiation was suggested [91, 93].
In wound healing and embryogenesis, maintenance of
VSMC differentiation might be a beneficial effect of
NOX4 [91]. However, in IRI and cardiac pressure overload,
NOX4 in cardiomyocytes and cardiac fibroblasts may have
a more ambivalent role: They seem to stimulate proliferation
and differentiation of cardiac fibroblasts into myofibro-
blasts, which may lead to fibrosis, cardiac remodeling, and
heart failure [92, 115]. In human PASMC, NOX4 also
mediated proliferation in response to hypoxia, but also to
factors such as transforming growth factor β1 or urotensin-
II, which can contribute to vascular remodeling in different
disease states [51, 116, 117]. Moreover, hypertrophic stimuli
such as angiotensin II and pressure overload increased
NOX4 expression in cardiac myocytes [118]. Aged mice
overexpressing NOX4 in the heart showed increased fibro-
sis and apoptosis of cardiomyocytes [118]. Interestingly,
overexpression of HIF-1α increased proliferation in
PASMC, but not when NOX4 was depleted by shRNA
[51]. Thus, an additional role of HIF-1α in the VSMC
proliferative response seems likely. Altogether NOX4 seems
to be involved in regulating the growth and differentiation of
VSMC and cardiac cells, which in the post-reperfusion
phase might lead to remodeling and formation of fibrosis.
Unfortunately, there are no in vivo data on the effect of
NOX4 on the long-term remodeling after IRI. The in vivo
and in vitro studies discussed are summarized in Tables 2
and 3, respectively.
Other sources of ROS in IRI
As already mentioned, other sources of ROS distinct from
NADPH oxidases generate ROS under nonphysiological
conditions. This indicates that these sources might also play
a role in IRI. For example, xanthine oxidoreductase (XOR)
catalyses the formation of xanthine and uric acid from
hypoxanthine. It can exist in two different forms, xanthine
dehydrogenase that transfers electrons to NAD+ and xan-
thine oxidase, which cannot bind NAD+, thus transferring
electrons directly to molecular oxygen [119]. Under condi-
tions of inflammation or oxidative stress, xanthine dehydro-
genase can be posttranslationally modified to the ROS-
producing xanthine oxidase [20, 119]. The evidence for a
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Table 2 In vivo studies on the role of NADPH oxidases in IRI
Heart







Infarct size Survival Inflammation
p47phox KO vs WT mice LAD ligation 4 week ↓ ↓ Ø ↑ n.a. [64]




24 h Ø Ø Ø n.a. ↑ [107]
NOX2 KO vs WT mice LAD ligation 8 week Ø Ø Ø ↓ n.a. [105]
NOX2 KO vs WT mice LAD ligation 4 week ↓ ↓ Ø Ø n.a. [65]
NOX2 KO vs WT mice LAD ligation 4 week n.a. n.a. Ø n.a. Ø [66]
Brain






NOX1 KO vs WT mice tMCAO (30 min) 24 h Ø Ø n.a. n.a. [83]
NOX1 KO vs WT mice tMCAO (60 min) 24 h Ø Ø n.a. n.a. [62]
NOX1 KO vs WT mice tMCAO (60 min) ↓ ↑ n.a. ↓ [84]
NOX2 KO vs WT mice tMCAO (60 min) 24 and 72 h ↓ n.a. ↓ n.a. [77]
NOX2 KO vs WT mice tMCAO (75 min) 24 and 72 h ↓ ↑ ↓ n.a. [76]
NOX2 KO vs WT mice tMCAO (120 min) 1/2/24 h 24 h, ↓; 2 h,
Ø
n.a. n.a. 1 h, ↓ [86]
NOX2 KO vs WT mice tMCAO (60 min) 24 h Ø Ø n.a. n.a. [62]
NOX2 KO vs WT mice tMCAO (25 min) 72 h ↓ n.a. n.a. n.a. [150]
NOX2 KO vs WT mice tMCAO (120 min) 24 h ↓ n.a. Ø n.a. [87]
NOX4 KO vs WT mice tMCAO (60 min) 24 h ↓ ↑ n.a. ↓ [62]
pMCAO 24 h ↓ ↑ n.a. n.a.
PT 24 h ↓ n.a. n.a. n.a.
WT mice treated with
VAS2870
TMCAO 24 h ↓ ↑ n.a. n.a.
Hindlimb
Animal model Ischemic model Time endpoint Outcomes Reference
Blood flow
recovery
Capillary density Ischemic muscle injury
NOX1 KO vs WT mice FA ligation 2 weeks ↑ n.a. n.a. [114]
NOX2 KO vs WT mice FA excision 2 weeks ↓ n.a. ↑ [102]
NOX2 KO vs WT mice FA ligation 3 weeks ↓ ↓ n.a. [104]
Diabetic NOX2 KO vs
diabetic WT mice
↑ ↑ n.a.
NOX2 KO vs WT mice FA excision 2 weeks ↑ ↑ n.a. [103]
NOX2 KO vs WT mice after
chronic smoke exposure
↑ ↑ n.a.
NOX2 KO vs WT mice FA ligation 2 weeks ↓ n.a. n.a. [114]
NOX2 KO vs WT mice FA excision 1 week ↓ ↓ n.a. [101]
NOX2 KO vs WT mice FAV excision 2 weeks ↓ n.a. n.a. [100]
WT mice after adenoviral
NOX4 injection vs WT
mice
FA ligation 4 weeks ↑ ↑ n.a. [67]
NOX4 KO vs WT mice FA ligation 2 weeks ↑ n.a. ↑ [114]




Animal model Ischemic model Time point
investigated
Outcomes Reference
Edema Kfc Pulmonary function
NOX1 KO vs WT mice Isolated perfused
lung ischemia
(90 min)
30/60/90 min Ø Ø n.a. [90]
NOX2 KO vs WT mice ↓ ↓ n.a.
NOX4 KO vs WT mice Ø Ø n.a.
p47phox KO vs WT mice Lung hilar ligation
(60 min)
120 min ↓ n.a ↑ [78]
n.a. not applicable, BBB blood–brain barrier, FA femoral artery, LAD left anterior descending coronary artery, pMCAO permanent middle cerebral
artery occlusion, tMCAO transient middle cerebral artery occlusion, Ø no change
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Table 3 In vitro studies on the role of NAPDH oxidases in IRI
Cell/tissue Treatment Outcome Reference
ROS production and NOX expression
H9c2 cardiac cells I/R ↑ ROS, ↑ p47phox protein, ↑ NOX2 protein [80]
I/R+DPI or apocynin ↓ ROS increase
H9c2 cardiac cells Metabolic inhibition (ischemia) ↑ ROS, ↑ NOX2 mRNA, ↑ apoptosis [81]
Metabolic inhibition+DPI or
apocynin
↓ ROS increase, ↓ apoptosis
Human PASMC Hypoxia ↑ NOX4 mRNA and protein and HIF-1α mRNA and protein [51]
HepG2 cells Hypoxia and overexpression HIF-1α ↑ Cell proliferation and ROS production
HEK293 Hypoxia, overexpression HIF-1α
and depletion NOX4 with shRNA
↓ of increased proliferation and ROS production
Angiogenesis
NIH 3T3 cells Transfection of cells with NOX1,
then injection into athymic mice
↑ VEGF expression, ↑ H2O2 production [108]
DU-145 ↑ Growth of tumours with more vascularization
NIH-3T3 cells Transfection of cells with NOX1,
then overexpression catalase
↑ Cell proliferation, ↑ H2O2 production, [110]
Reversion of NOX1 induced phenotype
Human and bovine EC Adenoviral overexpression or
knockdown NOX4




NOX4 Tg and WT mice
– ↑ Capillary sprouting in Tg aortas
HMEC and HUVEC siRNA to NOX4 ↓ Tube formation and ↓wound healing [112]
HMEC Adenoviral transfection NOX4 ↓ EC migration and proliferation
↓ Tube formation but ↑wound healing
HUVEC NOX2 antisense ↓ VEGF induced ROS production, proliferation, and migration [98]
HCAEC/HUVEC p47phox siRNA ↓ VEGF mediated phosphorylation of VEGFR2 [99]
Human endothelial cells Urotensin ↑ Formation capillary like structures in Matrigel [73]
Mouse vena cava explants Urotensin in NOX2 depleted cells ↓ Formation capillary like structures in Matrigel
Urotensin ↑ Sprouting in Matrigel
Remodeling
VSMC from aortas of SD
rats
– High NOX4 mRNA in differentiating cells, low NOX4 in
dedifferentiating cells
[91]
NOX4 siRNA/antisense Low NOX1 mRNA in differentiating cells, high NOX1 in
dedifferentiating cells
↓ Differentiation markers and ↓ contractile type stress fibers
Human primary cardiac
fibroblasts
TGF-β1 ↑ NOX4 mRNA, Ø NOX1, NOX2 and NOX5 mRNA [92]
NOX4 siRNA ↓ Basal and TGF-β1 stimulated ROS production, ↓ SM α-actin
mRNA and protein
NOX5 siRNA Ø Basal and TGF-β1 stimulated ROS production
Aortic VSMC from NOX1
Tg and WT mice
AT-II ↑ ROS production in Tg, blood pressure elevation in vivo higher in
Tg, greater hypertrophy (aortic medial thickness) in Tg
[109]
Mouse ESC siRNA against NOX4, shRNA
against NOX4 siRNA






AT-II, TAC, and aging ↑ NOX4 protein expression [118]
Cardiomyocytes from
mice
NOX4 overexpression Cell size Ø, ↑ apoptosis in overexpressing cells
Human PASMC Urotensin-II ↑ p22phox and NOX4 protein expression, ↑ROS production, ↓ of
increased ROS production
[116]
Urotensin-II and antisense vectors
against p22phox and NOX4
Human PASMC TGF-β1 ↑ NOX4 mRNA and protein expression and ROS production [117]
TGF-β1 and siRNA against NOX4 ↓ TGF-β1 induced proliferation
AT-II angiotensin II, DU145 epithelial cell line derived from human prostate tumor, EB embryoid bodies, ESC embryonic stem cells, HEK293
human embryonic kidney cells, HCAEC human coronary artery endothelial cells, HepG2 human hepatoblastoma cells, HMEC human microvas-
cular endothelial cells, HUVEC human umbilical vein endothelial cells, NIH 3T3 cells mouse embryonic fibroblasts, PASMC pulmonary artery
smooth muscle cells, SD rats Sprague–Dawley rats, siRNA short interference RNA, shRNA short hairpin RNA, riRNA ribosomal RNA, TAC
transient aortic constriction, VEGF vascular endothelial growth factor, VSMC vascular smooth muscle cells, Ø no change
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role of XOR in IRI is controversial, showing both positive
and negative roles as reviewed in [16, 20, 119].
NO synthase catalyses the formation of NO from L-argi-
nine, using tetrahydrobiopterin (BH4) as an essential, redox-
sensitive cofactor. NOS, too, can have double-edged roles
within the vasculature: NO is beneficial by mediating, for
example, vasorelaxation, anticoagulant, and antiprolifera-
tive properties [10]. However, during IRI, ROS uncouple
NOS by oxidizing BH4 [120]. NOS itself then produces
ROS instead of NO [10, 12, 121]. In addition, NO can react
with superoxide to form toxic peroxynitrite [122, 123],
causing further cell and tissue damage.
Mitochondria have also been described as being major
contributors to ROS production in IRI, especially in the
heart [17, 124–127]. Mitochondria form ROS via electron
leakage from the electron transport chain during oxidative
phosphorylation at different complexes [128] or via less
common ways involving monoamine oxidases or p66Shc
protein [18]. Similar to the case of NOS, ROS produced by
mitochondria or by other sources can lead to a further
increased production of ROS: ROS induced ROS release
[129, 130]. Mitochondrial ROS have been shown to also
play a role in ischemic preconditioning [131, 132].
Interplay between different sources of ROS can also be
one of the mechanisms contributing to IRI [11, 22, 128].
NOX4, for example, has been shown to localize in mito-
chondria, indicating that NOX4 might produce mitochon-
drial ROS [40]. The ROS produced by NADPH oxidases
can then trigger mitochondrial dysfunction, leading to in-
creased ROS production and, vice versa, ROS produced by
mitochondria can activate NADPH oxidases. This has re-
cently been reviewed in more detail elsewhere [128].
Nevertheless, it has yet to be established which source(s)
of ROS are the pathologically relevant ones in IRI. Howev-
er, again, NADPH oxidases are the only enzymes with the
sole function of generating ROS. Therefore, targeting
NADPH oxidases seems a new promising therapeutic strat-
egy, which seems superior compared to using antioxidants,
as will be discussed in the following section.
Therapeutic strategies
Antioxidants
As ROS and oxidative stress are likely major players in IRI,
attempts to prevent and treat related disorders with antiox-
idant supplements seemed plausible. Indeed, many clinical
trials testing the effects of antioxidant application have been
performed.
Some rather small clinical trials tested the acute or sub-
acute therapeutic effects of antioxidants in patients with I/R-
related disorders, with conflicting results. For example, in
patients undergoing aortic cross-clamping, oral supplemen-
tation of vitamin E (60 mg for 8 days presurgery) prevented
the overproduction of ROS and diminished muscle damage
in the lower limbs [133]. However, such a preventive inter-
vention is, by definition, excluded in post-infarct or post-
stroke therapies. Nevertheless, in patients with diabetes, but
not in nondiabetic patients, a reduction in 30-day mortality
after acute MI was found when patients were treated with
high doses of vitamin C (1,000 mg intravenously [IV] in
12 h, 400 mg orally) and vitamin E (200 mg, two times
daily) for 30 days [6]. In contrast, human superoxide dis-
mutase (IV bolus of 10 mg/kg followed by infusion of
0.2 mg/kg/min for 60 min) did not show any effect after
acute MI in patients undergoing percutaneous transluminal
coronary angioplasty [134]. In smokers with MI, oral sup-
plementation of vitamin E (50 mg daily) did not reduce the
incidence of recurrent MI [135]. Alarmingly, the adminis-
tration of vitamin C (2 g IV 2 h prior to surgery) in patients
undergoing elective I/R (aortic clamping) promoted iron-
induced oxidative lipid damage via a Fenton-type reaction.
The subsequent release of lactate dehydrogenase into the
systemic circulation may have catalyzed the formation of
second-generation radicals implicated in the regulation of
vascular permeability and angiogenesis [136]. The reasons
for the conflicting results are not known, but may be caused
by the use of different antioxidants, doses, and timing as
well as patient collectives. Nevertheless, as these studies
only included relatively small patient numbers, they rather
have a pilot character.
Many large and long trials tested antioxidant supplements
for primary and secondary prevention of I/R events. Despite
the huge patient numbers, study results are conflicting [3, 5,
6, 135, 137, 138]. However, several meta-analyses suggest
that the application of antioxidants does not improve car-
diovascular mortality and morbidity. In contrast, untargeted
supplementation of antioxidants may even be harmful [5,
27, 29, 30, 139]. Thus, although ROS play an important role
in IRI, antioxidants failed to prevent related disorders. Sev-
eral explanations for this failure have been proposed. For
example, antioxidants given orally might not penetrate into
the vascular wall; scavenging of radicals can convert anti-
oxidants to radicals themselves exerting pro-oxidant effects;
and the timing of the application might not be right, since
ROS already play a role in the initiation of cardiovascular
diseases [27, 139]. Furthermore, antioxidants—if they reach
the target tissue—cannot distinguish between good and bad
ROS.
Thus, unraveling the role of ROS and their sources at
different time points in IRI is crucial for designing the
optimal therapeutic approach. Preventing the formation of
disease-triggering ROS at the right time, instead of scaveng-
ing them after they have been formed, seems a better ther-
apeutic approach.
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NADPH oxidases as therapeutic targets in IRI
NADPH oxidases are crucial players in all phases of IRI.
Thus, interfering with the NADPH oxidase function is a
promising strategy for treating IRI. However, important
issues need to be considered: First, timing is likely to be
crucial, since NADPH oxidases and ROS play different
roles, depending on the time course of IRI. Second,
isoform-specific differences or organ/cell-specific effects
have to be taken into account. Third, the amount of ROS
is important, since low amounts of ROS are needed for
physiologic functions such as regulation of cell growth
and differentiation [11, 12], whereas increased levels sur-
pass endogenous antioxidant defense and cause cell
damage.
The underlying mechanisms of all these factors are only
incompletely understood. During ischemia, NADPH oxi-
dases interact with HIF [49–51, 53–55] and may play a role
in oxygen sensing [47, 48, 57]. However, the involvement
of individual NOX isoforms and whether inhibition or rather
enhancing NADPH oxidase activity during this phase is the
appropriate therapeutic approach is unclear.
During reperfusion, NADPH oxidase inhibition could be
a new therapeutic option in acute events, such as stroke or
MI, if it is possible to intervene exactly during this period.
Patients diagnosed with ischemic stroke or MI could be
treated with NADPH oxidase inhibitors even before meas-
ures to establish reperfusion are taken. Also, in patients in
whom reperfusion has already occurred endogenously, treat-
ment with an NADPH oxidase inhibitor could be initiated in
the early phase of reperfusion. For example, in brain IRI,
inhibition of NOX4 post-reperfusion is beneficial in mice
after an ischemic stroke [62]. NOX4 has been found in
mitochondria [40]. As mitochondrial ROS likely have det-
rimental roles in the acute damaging phase after I/R of the
heart [124], reducing mitochondrial ROS generation by
NOX4 inhibition is an attractive strategy. NOX2 may also
be a good target in this condition, since an inflammatory
reaction and disturbed BBB promotes the influx of neutro-
phils into the ischemic brain area [85]. However, data re-
garding NOX2 are conflicting [88]. In heart IRI, even more
NOX isoforms may play a role [22]. Importantly, NOX5, the
only NOX isoform, which is activated by calcium, is a
potential target to reduce oxidative stress in VSMC [39,
140] as well as in EC [38] and possibly also directly in the
heart. Unfortunately, due to the lack of NOX5 in rats and
mice, no in vivo data on the role of NOX5 in animal models
of MI are available.
During the third post-reperfusion phase, ROS appear to
be needed for angiogenesis [15]. However, at the same time,
they can be detrimental in promoting hypertrophy or dilata-
tion. Here, not only the amount of ROS and the place where
they are produced, but also the underlying causes of
remodeling seem crucial, as is shown by divergent results
in different pressure overload models [141, 142]. In chronic
ischemic diseases, such as peripheral artery disease (PAD),
the inhibition of NADPH oxidases could lead to an even
more impaired blood flow [114] via interfering with angio-
genesis. Here, NADPH oxidase-stimulated angiogenesis
could lead to a better preserved vascularization and oxygen
delivery within the peripheral tissues [67]. Thus, the activa-
tion of specific NOX isoforms at specific locations may here
be a therapeutic option for PAD patients. Since NOX1,
NOX2, and NOX4 are expressed in both VSMCs and ECs
[22], they all seem to be possible targets in chronic ischemic
disease states.
NADPH oxidase inhibitors
As is clear from the discussion in the previous chapter,
complete inhibition of NADPH oxidase activities may not
be a good strategy. Rather, it is important to delineate the
precise roles of individual NOX isoforms, and it may turn
out that one isoform should be inhibited, while another
should be left untouched or even activated. Isoform-
specific NOX inhibitors developed as therapeutic drugs
could be used at specific time points during IRI.
Due to the high degree of structural similarity among the
NOX enzymes [22], the development of isoform-selective
NADPH oxidase inhibitors seems difficult. However, to
avoid unforeseeable and potentially severe side effects of
unselective NOX inhibition, this is highly desired. Current-
ly, there is only one NOX isoform-specific inhibitor pub-
lished, which is the NOX2 inhibitory peptide gp91ds-tat
[143]. However, peptides are not orally bioavailable and
probably do not show suitable pharmacokinetic parameters
for clinical applications. Thus, small-molecule inhibitors are
better suited. Nevertheless, published small-molecule
NADPH oxidase inhibitors with some degree of selectivity
for one NOX isoform, such as ML171 [144] and M090
[145] (NOX1 selectivity), do not seem to have satisfying
pharmacokinetic properties. Other inhibitors, both isoform-
selective and isoform-unselective, have not yet been thor-
oughly investigated for off-target effects and toxicity, for
example, fulvene-5, VAS2870, M090, and to some degree,
ML171 [82, 144–146]. VAS2870 has been shown to reduce
ROS production in vitro [147] and to diminish brain damage
after stroke in vivo [62]. However, initially, VAS2870
seemed to be specific for NADPH oxidases [138], but
recently, potential off-target effects of VAS2870 have been
reported [148] with thiol alkylation as the likely mechanism
of action of VAS2870-mediated NADPH oxidase inhibition.
Clearly, the importance of this off-target alkylation or pos-
sible other off-target effects of VAS2870 need further anal-
ysis. The first inhibitor showing suitable toxicity and high
oral bioavailability was the NOX1 and NOX4 inhibitor
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GKT136901 [149], which was further optimized to
GKT137831. The latter compound is now in a phase I
clinical study for the indication diabetic nephropathy.
In summary, (isoform)-specific NOX inhibitors or stim-
ulators with a good pharmacodynamic and pharmacokinetic
profile would be a significant step forward in the treatment
of diseases, in which IRI plays a role.
Summary and outlook
Isoform-selective inhibition of NADPH oxidases seems to
be a promising strategy to treat stroke and MI. Instead of
scavenging ROS with antioxidants, selective blockade of
ROS production at pathologically important sites may open
new doors for therapies. Timing of selective NOX blockade
may be of utmost importance because of the opposing
effects in the different phases of IRI. In the post-
reperfusion phase, stimulation of NADPH oxidases might
even be an option. The same may hold true for more chronic
ischemic diseases, in which ROS likely mediate angiogen-
esis. Thus, it is clear that unraveling the precise sequence of
events and differential roles of the NADPH oxidase–ROS
axis is crucial for successful therapeutic clinical translation.
Keeping in mind the double-edged sword that NADPH
oxidases present, we must defeat the detrimental effects
and possibly embrace the beneficial effects at the same time.
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